Insmed, Inc. $INSM Shares Purchased by Fourth Dimension Wealth LLC

Fourth Dimension Wealth LLC increased its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 43.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,332 shares of the biopharmaceutical company’s stock after purchasing an additional 710 shares during the quarter. Fourth Dimension Wealth LLC’s holdings in Insmed were worth $235,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Bryce Point Capital LLC acquired a new stake in shares of Insmed during the second quarter worth $583,000. Corton Capital Inc. acquired a new stake in shares of Insmed during the second quarter worth $393,000. Amalgamated Bank lifted its holdings in shares of Insmed by 117.3% during the second quarter. Amalgamated Bank now owns 12,973 shares of the biopharmaceutical company’s stock worth $1,306,000 after purchasing an additional 7,003 shares during the period. Atria Investments Inc lifted its holdings in shares of Insmed by 75.3% during the second quarter. Atria Investments Inc now owns 16,810 shares of the biopharmaceutical company’s stock worth $1,692,000 after purchasing an additional 7,219 shares during the period. Finally, Assetmark Inc. lifted its holdings in shares of Insmed by 22.5% during the second quarter. Assetmark Inc. now owns 32,125 shares of the biopharmaceutical company’s stock worth $3,233,000 after purchasing an additional 5,892 shares during the period.

Insmed Trading Down 1.9%

Insmed stock opened at $182.77 on Wednesday. The stock has a market cap of $38.98 billion, a PE ratio of -32.01 and a beta of 1.05. The stock has a 50-day moving average price of $154.19 and a 200 day moving average price of $114.25. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $197.08. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. Equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on INSM. Cowen reaffirmed a “buy” rating on shares of Insmed in a report on Thursday, October 30th. Cantor Fitzgerald started coverage on Insmed in a report on Tuesday, October 28th. They issued an “overweight” rating and a $192.00 target price for the company. Jefferies Financial Group raised their target price on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. Bank of America raised their target price on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a report on Monday, October 27th. Finally, Wells Fargo & Company raised their target price on Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a report on Friday. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and an average target price of $173.29.

Insider Activity

In other Insmed news, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the sale, the chief executive officer owned 233,924 shares in the company, valued at $30,035,841.60. The trade was a 2.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the sale, the insider owned 54,902 shares of the company’s stock, valued at $7,899,848.78. This trade represents a 30.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 152,657 shares of company stock worth $21,442,198 in the last quarter. Corporate insiders own 3.00% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.